Predictive MiRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2023 Aug 18

PMID 37593370

Authors

Jingjing Fan

Yunjian Tang

Kunming Wang

Shu Yang

Binlin Ma

Affiliations

Soon will be listed here.

Abstract

Objective: The effect of chemotherapy in patients with breast cancer (BC) is uncertain. This study attempted to analyze serum microRNAs (miRNAs) in NAC resistant and sensitive BC patients and develop a miRNA-based nomogram model. To further help clinicians make treatment decisions for hormone receptor-positive patients.

Methods: A total of 110 BC patients with NAC were recruited and assigned in sensitive and resistant group, and 4 sensitive patients and 3 resistant patients were subjected to high-throughput sequencing. The functions of their target genes were analyzed by GO and KEGG. Five BC-related reported miRNAs were selected for expression pattern measurement by RT-qPCR and multivariate logistic analysis. The nomogram model was developed using R 4.0.1, and its predictive efficacy, consistency and clinical application value in development and validation groups were evaluated using ROC, calibration and decision curves.

Results: There were 44 differentially-expressed miRNAs in resistant BC patients. miR-3646, miR-4741, miR-6730-3p, miR-6831-5p and miR-8485 were candidate for resistance diagnosis in BC. Logistic multiple regression analysis showed that miR-4741 (or = 0.30, 95% CI = 0.08-0.63, P = 0.02) and miR-6831-5p (or = 0.48, 95% CI = 0.24-0.78, P = 0.01) were protective factors of BC resistance. The ROC curves showed a sensitivity of 0.884 and 0.750 for miR-4741 and miR-6831-5P as markers of resistance, suggesting that they can be used as independent risk factors for BC resistance. The other 3 miRNAs can be used as calibration factors to establish the risk prediction model of resistance in BC. In risk model, the prediction accuracy of resistance of BC is about 78%. 5-miRNA signature diagnostic models can help clinicians provide personalized treatment for NAC resistance BC patients to improve patient survival.

Conclusion: MiR-4741 and miR-6831-5p are independent risk factors for breast cancer resistance. This study constructed a nomogram model of NAC resistance in BC based on 5 differentially-expressed serum miRNAs.

Citing Articles

Identifying the Trends of Urinary microRNAs within Extracellular Vesicles for Esophageal Cancer.

Hisaoka K, Matsuda S, Minoura K, Yamaguchi H, Ichikawa Y, Mizunuma M Cancers (Basel). 2024; 16(9).

PMID: 38730650 PMC: 11083496. DOI: 10.3390/cancers16091698.

References

Ji X, Lu Y, Tian H, Meng X, Wei M, Cho W . Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019; 114:108800. DOI: 10.1016/j.biopha.2019.108800. View

Huang J, Li H, Ren G . Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. 2015; 47(3):840-8. DOI: 10.3892/ijo.2015.3084. View

Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A . Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers (Basel). 2021; 13(19). PMC: 8508299. DOI: 10.3390/cancers13194894. View

Baldassari F, Zerbinati C, Galasso M, Corra F, Minotti L, Agnoletto C . Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet. 2018; 9:174. PMC: 5968201. DOI: 10.3389/fgene.2018.00174. View

Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C . P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis. 2021; 12(12):1088. PMC: 8599616. DOI: 10.1038/s41419-021-04378-0. View

Mingorance Carvalho T, Brasil G, Jucoski T, Adamoski D, Lima R, Spautz C . MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer. Front Genet. 2022; 13:865472. PMC: 9280295. DOI: 10.3389/fgene.2022.865472. View

Zheng L, Xiang C, Li X, Guo Q, Gao L, Ni H . STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol. 2018; 11(1):72. PMC: 5977742. DOI: 10.1186/s13045-018-0613-5. View

Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M . Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2018; 110(1):408-419. PMC: 6317958. DOI: 10.1111/cas.13856. View

Grant E, Bucklain F, Ginn L, Laity P, Ciani B, Bryant H . Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines. PLoS One. 2022; 17(5):e0268300. PMC: 9135204. DOI: 10.1371/journal.pone.0268300. View

10.

Li Y, Zhang J, Wang B, Zhang H, He J, Wang K . A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer. Sci Rep. 2021; 11(1):11348. PMC: 8167133. DOI: 10.1038/s41598-021-91049-x. View

11.

Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W . The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review. Front Oncol. 2022; 12:899145. PMC: 9157424. DOI: 10.3389/fonc.2022.899145. View

12.

Davey M, Lowery A, Miller N, Kerin M . MicroRNA Expression Profiles and Breast Cancer Chemotherapy. Int J Mol Sci. 2021; 22(19). PMC: 8509379. DOI: 10.3390/ijms221910812. View

13.

Afify S, Seno M . Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation. Cancers (Basel). 2019; 11(3). PMC: 6468812. DOI: 10.3390/cancers11030345. View

14.

Frederiksen L, Sullivan R, Maxwell L, Macdonald-Goodfellow S, Adams M, Bennett B . Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res. 2007; 13(7):2199-206. DOI: 10.1158/1078-0432.CCR-06-1807. View

15.

Anastasiadi Z, Lianos G, Ignatiadou E, Harissis H, Mitsis M . Breast cancer in young women: an overview. Updates Surg. 2017; 69(3):313-317. DOI: 10.1007/s13304-017-0424-1. View

16.

Lou W, Liu J, Ding B, Xu L, Fan W . Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag Res. 2018; 10:4747-4757. PMC: 6205533. DOI: 10.2147/CMAR.S172722. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Haddad T, Goetz M . Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015; 22(5):1408-15. PMC: 4484769. DOI: 10.1245/s10434-015-4405-7. View

19.

Zhang X, Zhong S, Xu Y, Yu D, Ma T, Chen L . MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway. PLoS One. 2016; 11(4):e0153194. PMC: 4821636. DOI: 10.1371/journal.pone.0153194. View

20.

Pimentel F, Bonilla P, Ravishankar Y, Contag A, Gopal N, LaCour S . Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer. J Lab Autom. 2014; 20(5):574-88. DOI: 10.1177/2211068214561788. View